XT
AVIR icon

XTX Topco’s Atea Pharmaceuticals AVIR Stock Holding History

XTX Topco’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124K Buy
23,141
+12,702
+122% +$58.3K ﹤0.01% 3027
2025
Q4 		$37.3K Sell
10,439
-11,836
-53% -$37.6K ﹤0.01% 2903
2025
Q3 		$64.6K Sell
22,275
-64,849
-74% -$221K ﹤0.01% 2115
2025
Q2 		$314K Buy
+87,124
New +$260K 0.01% 1398
2023
Q2 		– Sell
-32,630
Closed -$109K – 1410
2023
Q1 		$109K Buy
+32,630
New +$132K 0.02% 1081

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

XTX Topco's AVIR Position: Q1 2026 in Review

XTX Topco increased its Atea Pharmaceuticals (AVIR) stake by 122% in Q1 2026, buying an estimated $58.3K and bringing the position to 23,141 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #3027.

XTX Topco first reported a position in AVIR in Q1 2023 and has held it in 5 quarters since. The position peaked at $314K in Q2 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • XTX Topco held 23,141 shares of Atea Pharmaceuticals worth $124K as of Q1 2026.
  • XTX Topco bought 12,702 Atea Pharmaceuticals shares in Q1 2026, an estimated $58.3K.
  • Atea Pharmaceuticals made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3027 holding.
  • XTX Topco first reported a position in Atea Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
  • XTX Topco's Atea Pharmaceuticals position peaked at $314K in Q2 2025.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.